Tenormin/myocardial infarction trial
Executive Summary
Treatment with Stuart's Tenormin (atenolol) in the early stages of suspected myocardial infarction reduced mortality by 15% compared to standard therapy, according to a study reported in the July 12 Lancet. The ISIS (International Study on Infarcet Survival) trial, conducted by Peter Sleight of Oxford University, was three and a half years in duration and involved 16,00 patients from 247 centers in 14 countries. Press release on study says "the most beneficial effects on mortality occurred in the first 48 hours" among patients who received I.V. beta blocker.